ATE475888T1 - Biomarker zur diagnose von alzheimer - Google Patents

Biomarker zur diagnose von alzheimer

Info

Publication number
ATE475888T1
ATE475888T1 AT08002793T AT08002793T ATE475888T1 AT E475888 T1 ATE475888 T1 AT E475888T1 AT 08002793 T AT08002793 T AT 08002793T AT 08002793 T AT08002793 T AT 08002793T AT E475888 T1 ATE475888 T1 AT E475888T1
Authority
AT
Austria
Prior art keywords
alzheimer
human
patients
disease
disclosed
Prior art date
Application number
AT08002793T
Other languages
English (en)
Inventor
Oezkan A Yalkinoglu
Gerhard Koenig
Denis Francois Hochstrasser
Jean-Charles Sanchez
Odile Carrette
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02018283A external-priority patent/EP1394549A1/de
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of ATE475888T1 publication Critical patent/ATE475888T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT08002793T 2002-08-23 2003-08-11 Biomarker zur diagnose von alzheimer ATE475888T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02018283A EP1394549A1 (de) 2002-08-23 2002-08-23 Biomarker zur Diagnose von Alzheimer Erkrankung
EP02026643 2002-11-29

Publications (1)

Publication Number Publication Date
ATE475888T1 true ATE475888T1 (de) 2010-08-15

Family

ID=31947886

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08002793T ATE475888T1 (de) 2002-08-23 2003-08-11 Biomarker zur diagnose von alzheimer
AT03792291T ATE403875T1 (de) 2002-08-23 2003-08-11 Polypeptid-biomarker zur diagnose von morbus alzheimer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03792291T ATE403875T1 (de) 2002-08-23 2003-08-11 Polypeptid-biomarker zur diagnose von morbus alzheimer

Country Status (10)

Country Link
EP (3) EP2221620B1 (de)
JP (1) JP4405919B2 (de)
AT (2) ATE475888T1 (de)
AU (3) AU2003251702B2 (de)
CA (6) CA2745569C (de)
DE (2) DE60322719D1 (de)
DK (3) DK1953556T3 (de)
ES (3) ES2311751T3 (de)
PT (1) PT1535076E (de)
WO (1) WO2004019043A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469312A1 (de) * 2003-04-18 2004-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnose der Alzheimer Krankheit
WO2005001483A2 (en) * 2003-06-27 2005-01-06 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Methods for diagnisis and differential diagnosis of dementia disorders
WO2005047484A2 (en) * 2003-11-07 2005-05-26 Ciphergen Biosystems, Inc. Biomarkers for alzheimer's disease
US7749716B2 (en) * 2004-05-18 2010-07-06 Vermilllion, Inc. Methods of detecting a fragment of neurosecretory protein VGF for diagnosing alzheimer's disease
GB0502068D0 (en) * 2005-02-01 2005-03-09 King S College London Screening method
US20100036094A1 (en) * 2005-04-06 2010-02-11 Mosaiques Diagnostics And Therapeutics Ag Polypeptide Markers for the Diagnosis of Alzheimer's Disease
JP2008547003A (ja) * 2005-06-16 2008-12-25 バーミリオン， インコーポレイテッド アルツハイマー病についてのバイオマーカーとしての神経分泌タンパク質ｖｇｆのフラグメント
WO2007098585A1 (en) * 2006-02-28 2007-09-07 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
JP5357746B2 (ja) * 2006-03-11 2013-12-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 末梢性の動脈疾患のためのバイオマーカーとしてのβ−２ミクログロブリン
GB0616230D0 (en) * 2006-08-16 2006-09-27 Univ Cambridge Tech Biomarkers and uses thereof
EP2117527B1 (de) 2007-02-08 2020-06-17 Med-Life Discoveries LP Verbindungen zur verwendung bei der behandlung von altersdemenz vom alzheimer-typ
EP2279420B1 (de) 2008-03-21 2014-01-29 Manuela G. Neuman VERFAHREN ZUR DIFFERENTIELLEN DIAGNOSE VON MORBUS ALZHEIMER GEGEN FRONTOTEMPORALE DEMENZ MIT FAS-L, TNF-alpha UND ccCK-18 ALS BIOMARKER
WO2010034072A1 (en) * 2008-09-26 2010-04-01 The University Of Melbourne Alzheimer's disease biomarkers
JP2010271078A (ja) 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
BR112016012968A2 (pt) 2013-12-09 2017-08-08 Univ Leland Stanford Junior Métodos e composições para o tratamento de condições associadas com o envelhecimento
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
GB201322094D0 (en) * 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease
CA2989138C (en) 2015-06-15 2022-11-22 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating cognitive impairment or decline comprising tissue inhibitor of mettaloproteinase-2 (timp-2)
KR102572009B1 (ko) * 2020-10-21 2023-08-29 순천향대학교 산학협력단 시스타틴 c를 포함하는 퇴행성 신경 질환 진단용 바이오마커 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
JP2002531063A (ja) * 1998-10-23 2002-09-24 ローゲル ニッシェ アルツハイマー症の診断又は予後の方法
WO2001062787A1 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Limited Diagnosis and treatment of bipolar affective disorder
WO2001071357A2 (en) * 2000-03-20 2001-09-27 Oxford Glycosciences (Uk) Limited Diagnosis and treatment of breast cancer
US20020164668A1 (en) * 2000-04-03 2002-11-07 Durham L. Kathryn Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2002082075A2 (de) * 2001-04-06 2002-10-17 Biovision Ag Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien
AU2002330215A1 (en) * 2001-10-03 2003-04-14 Oxford Glycosciences (Uk) Ltd. Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease

Also Published As

Publication number Publication date
AU2010212317A1 (en) 2010-09-09
AU2003251702B2 (en) 2010-06-03
JP2005536729A (ja) 2005-12-02
DK1535076T3 (da) 2008-11-24
CA2745724C (en) 2015-06-02
CA2745569C (en) 2015-07-14
CA2745569A1 (en) 2004-03-04
EP2221620A3 (de) 2010-11-24
ES2436318T3 (es) 2013-12-30
WO2004019043A3 (en) 2004-06-24
AU2003251702A1 (en) 2004-03-11
EP1953556A3 (de) 2008-11-26
EP2221620A2 (de) 2010-08-25
ES2311751T3 (es) 2009-02-16
DK2221620T3 (da) 2014-01-06
EP1953556A2 (de) 2008-08-06
DK1953556T3 (da) 2010-10-25
DE60333608D1 (de) 2010-09-09
CA2746000C (en) 2014-10-21
EP1535076B1 (de) 2008-08-06
CA2745731A1 (en) 2004-03-04
EP1953556B1 (de) 2010-07-28
CA2496321E (en) 2004-03-04
EP2221620B1 (de) 2013-10-02
CA2746000A1 (en) 2004-03-04
CA2745998A1 (en) 2004-03-04
AU2010212316A1 (en) 2010-09-09
CA2745998C (en) 2013-11-26
CA2745724A1 (en) 2004-03-04
DE60322719D1 (de) 2008-09-18
WO2004019043A2 (en) 2004-03-04
JP4405919B2 (ja) 2010-01-27
EP1535076A2 (de) 2005-06-01
ES2347924T3 (es) 2010-11-25
CA2496321A1 (en) 2004-03-04
CA2496321C (en) 2013-05-21
PT1535076E (pt) 2008-11-03
CA2745731C (en) 2015-05-12
ATE403875T1 (de) 2008-08-15
AU2010212317B2 (en) 2013-01-10
AU2010212316B2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
DE60333608D1 (de) Biomarker zur Diagnose von Alzheimer
ATE535535T1 (de) Methoden für die diagnose von demenz und anderen neurologischen erkrankungen
WO2003070894A3 (en) A non-invasive diagnostic test utilizing histone modification markers
NO20050186L (no) Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser
BRPI0414030A (pt) método para detectar desordens neoplásicas em uma amostra corporal solubilizada
ATE386942T1 (de) Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer
ATE440536T1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
WO2005083440A3 (en) Identification of cancer protein biomarkers using proteomic techniques
DE502005009914D1 (de) Bestimmung von felinem und caninem probnp
DE60233949D1 (de) Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
DE602004028513D1 (de) Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
DE60326153D1 (de) Verfahren zur diagnose von morbus alzheimer
WO2002088303A3 (en) Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
JP4452715B2 (ja) 特定のペプチドを自閉症の指標として利用する方法
WO2007062363A3 (en) Method for diagnosing a person having sjogren's syndrome
BR0007702A (pt) Método e kit de diagnóstico para diagnose de endometriose
ATE421693T1 (de) Proteine in der diabetes-proteomanalyse
ATE352037T1 (de) Immunochromatographiesystem und verfahren zur gleichzeitigen identifikation von aga-und t-tg- antikörpern und verwendung dafür zur diagnose der zöliakiekrankheit
CN106661608A (zh) 十二指肠液试样作为来自胰液的成分检测用试样的适性评价方法
DE60334200D1 (de) Verfahren zur messung von neprilysinaktivität
AU2003299389A8 (en) PRP detection method using an aminoglycoside antibiotic
ATE489634T1 (de) In vitro methode zur klinischen diagnose.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1953556

Country of ref document: EP